Hepatitis/MASH

Australia on track to achieve World Health Organization targets for eliminating hepatitis C virus over the next 10 to 15 years.

An association between hepatitis C virus infection and incident diabetes found among patients who underwent kidney transplantation.

One-time, universal screening of hepatitis C virus (HCV) in the general population is cost-effective and could reduce rates of drug-related HCV cases.

Recent preclinical and population evidence shows cannabis modulates inflammatory and fibrotic processes in the liver, which is promising for treating the symptoms of hepatitis C virus.

Study investigates whether direct-acting antiviral drugs for hepatitis C virus increase the risk of developing hepatocellular carcinoma.

The national Veterans Health Administration Corporate Data Warehouse could be key in revealing accurate data on the use of direct-acting antivirals in the treatment of chronic hepatitis C virus.

Glecaprevir/pibrentasvir found to be effective in clinical trials treating patients with hepatitis C virus also being treated for opioid substitution therapy.

Top news of the day from across the health care landscape.

A new review of clinical trial data show the combination therapy elbasvir/grazoprevir (EBR/GR) has high rates of efficacy for patients with genotypes 1a, 1b, and 4 chronic hepatitis C (HCV) infection.

In light of new evidence supporting the efficacy of hepatitis C virus (HCV) treatments in individuals who use or inject drugs, researchers are urging the removal of restrictions that prevent recent drug users from accessing lifesaving HCV therapies.

Based on evidence from a systematic review, researchers are calling for increased access to lifesaving hepatitis C treatments for injection drug users.

Top news of the week from Specialty Pharmacy Times.

Officials with Gilead Sciences, Inc. plan to launch authorized generic versions of Epclusa and Harvoni.

Study establishes real-world efficacy, tolerability, and safety profile of sofosbuvir-based regimens in patients with chronic hepatitis C who have compensated liver cirrhosis.

Top news of the day from across the health care landscape.

Study shows that it’s cost-effective to use the livers of HCV-positive patients even with the cost of direct-acting antiviral drugs to cure the virus.

Researchers have identified a potential point of intervention that could prevent the progression of liver damage to cancer.

Study identifies receptor as potential target for reversing liver damage and preventing progression to cancer.

Presenters at the International Pharmaceutical Federation (FIP) World Congress in Glasgow, Scotland identified the current landscape of Hepatitis C, how pharmacists can position themselves to aid in point of care testing, and ways to better educate patients and providers.

In its multiple-ascending dose trial, ARO-HBV demonstrated reductions in circulating hepatitis B virus surface antigen.

Officials with the FDA have approved Grifols’ new formulation of immune globulin (GamaSTAN) for hepatitis A virus and measles post-exposure prophylaxis.

The new formulation is the only immune globulin available in the United States that is approved for post-exposure protection against hepatitis A and measles.

If proven effective, GLS-6150 could be the first vaccine to protect against hepatitis C virus infection.

Study shows the safety and efficacy of treatment with sofosbuvir and velpatasvir in adults with recurrent chronic genotypes 1-4 HCV infection after liver transplant.